Author: Biocytogen Boston

The Key Technology Of Biocytogen’s Fully Human Antibody Renmab Platform Has Been Granted A Chinese Patent

July 12, 2023

Beijing, China, July 11, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced its independently developed key technology of RenMabTM platform has been granted a Chinese patent. The patent is related to the key technology of Biocytogen’s fully human antibody RenMab platform and the company has recently received the patent certificate issued by […]

Read More

Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics

July 5, 2023

Exclusive License Agreement for an Oncological Target Antibody to Develop Best-In-Class ADC Beijing, China and London, UK, July 5, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics today announces an antibody license agreement with Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate […]

Read More

Webinar: Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety

June 26, 2023

  Our webinar “Bispecific Antibody-Drug Conjugates (BsADCs): An Emerging, Promising Anti-Cancer Therapeutic Modality With Improved Efficacy And Safety” was live at 12:00 PM EDT on July 19th, 2023.  About the Webinar Bispecific ADCs (BsADCs) are emerging as a promising modality in anti-cancer therapies. BsADCs offer increased target diversity and selectivity from the dual targeting antibody moiety, […]

Read More

Join us at Chinese American Diabetes Association 2023 Annual Meeting: June 20-23

Date: June 20-23, 2023
Location: San Diego, CA

Join us at the Chinese American Diabetes Association 2023 Annual Meeting in San Diego, CA from June 20-23! Learn more about our custom model generation services and metabolic disease modeling services to support your therapeutic discovery and preclinical validation!  Attend the meeting Talk to us at the booth! The mission of CADA is to provide […]

Read More

Visit Our Bispecific ADC Poster at IO Summit Europe 2023!

June 14, 2023

Visit Our Bispecific ADC Poster at IO Summit Europe 2023! Biocytogen’s antibody Business Development & Licensing team is excited to attend the upcoming Immuno-Oncology Summit Europe 2023 conference, held in London, UK from June 20-22, 2023. The team will present a poster (Session B04) at the event, entitled “YH013, a Common Light Chain Bispecific ADC […]

Read More

Join us at the 6th Annual Next-Gen Immuno-Oncology: June 22-23

Date: June 22-23, 2023
Location: Boston

Join us in our presentation and meet with our team if you are also attending 6th Annual Next-Gen Immuno-Oncology from June 22-23 in Boston! Learn more about our antibody discovery services and other platforms to help support your research projects. Presentation: Speaker: Jenna Frame, PhD, Sr. Manager, Scientific Communications & Marketing, Biocytogen Time and Date: […]

Read More

Webinar: Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMab, RenLite & RenNano Mice

June 5, 2023

  Our webinar “Generating Fully Human Antibodies and Antibody-based Therapeutics with RenMabTM, RenLiteⓇ & RenNanoTM Mice” was live at 1:00 PM EDT on June 20th, 2023.  About the Webinar Therapeutic development of antibodies and antibody-based drugs is a multi-year process that involves high cost and significant risk. In recent years, a common discovery approach to ensure […]

Read More

Biocytogen Opens San Francisco Office to Accelerate Globalization

May 31, 2023

Beijing, China and San Francisco, CA, May 31, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA. The new space will aim to accelerate the globalization of Biocytogen’s businesses. San Francisco is renowned as a hub of the biotechnology industry, and […]

Read More

Biocytogen to Present Pipeline Assets and R&D Progress at BIO International Convention, June 5-8, 2023

May 24, 2023

Biocytogen’s antibody BD and licensing (BDL) team will be delivering an oral presentation on Monday, June 5th at the 2023 BIO International Convention in Boston, taking place from June 5-8. The presentation will highlight Biocytogen’s clinical and preclinical pipeline assets, 6 fully human antibody discovery platforms, as well as the progress of Project Integrum, an […]

Read More

Meet Biocytogen’s APAC Business Development Team at 70th JALAS 2023!

May 19, 2023

Biocytogen’s Asia-Pacific business development team is pleased to exhibit at the 70th Japanese Association for Laboratory Animal Science (JALAS) annual meeting from May 24-26, 2023 in Tsukuba, Japan! Join us at Booth D-3 to learn more about how BioMice models and services, our fully human antibody discovery platforms and antibody assets can help you develop […]

Read More

Back to top
WordPress Double Opt-in by Forge12